Summary of Key Points Core Viewpoint - The announcement details the conversion results and share changes related to the "Jianyou Convertible Bonds" issued by Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd, highlighting the low conversion rate and the remaining unconverted bonds. Group 1: Conversion Status - As of June 30, 2025, a total of RMB 719,000 of "Jianyou Convertible Bonds" have been converted into ordinary shares, with RMB 7,000 of the bonds being repurchased [1][3] - The amount of unconverted "Jianyou Convertible Bonds" as of June 30, 2025, is RMB 502,464,000, which represents 99.86% of the total issuance [1][3] Group 2: Issuance Overview - The company issued 5,031,900 convertible bonds with a total value of RMB 5.0319 billion, with a maturity of 6 years, approved by the China Securities Regulatory Commission [1][2] - The bonds were listed on the Shanghai Stock Exchange starting from May 22, 2020, under the code "113579" [1][2] Group 3: Conversion Price Adjustments - The initial conversion price was set at RMB 54.97 per share, which has been adjusted multiple times due to various corporate actions, with the latest adjustment bringing the price down to RMB 24.34 per share effective from June 5, 2025 [2][3] Group 4: Share Capital Changes - The total share capital remained unchanged at 1,615,634,969 shares as of June 30, 2025, with no new shares issued from the conversion of the bonds [4]

Core Viewpoint - Jingze Biopharmaceutical (Hefei) Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, focusing on reproductive and ophthalmic drugs, but has faced consecutive net losses in 2023 and 2024 due to no products being commercially available [1][2][9]. Group 1: Product Pipeline and Commercialization - The company has eight drug candidates, with three in late-stage development, one approved for market, and one under New Drug Application (NDA) submission [4]. - The core product JZB30, a recombinant human follicle-stimulating hormone (rhFSH) lyophilized injection, is expected to generate revenue by 2026 after receiving NDA approval in April 2025 [5][6]. - Another core product, JZB05, targets wet age-related macular degeneration (wAMD) and diabetic macular edema (DME), and is positioned as a biosimilar to the leading ophthalmic drug, Aflibercept, which is projected to have sales of $9.5 billion in 2024 [5]. Group 2: Financial Performance and Challenges - The company reported net losses of approximately 246 million yuan and 243 million yuan for 2023 and 2024, respectively, primarily due to ongoing R&D and administrative expenses [9]. - As of April 30, 2025, the company's current liabilities reached approximately 1.401 billion yuan, indicating a decline in liquidity, with current and quick ratios at 5.7% and 5.5%, respectively [9]. - The company has previously sought funding through equity financing and loans, with cash reserves of 68.586 million yuan and 27.08 million yuan as of the end of 2024 and April 2025, respectively [9]. Group 3: Market Competition - The commercialization of JZB30 faces significant competition, with six other similar biopharmaceuticals already on the market and four more in clinical development targeting the same mechanism [7][8]. - JZB05 and JZB33 also face competition from both commercialized products and candidates in clinical stages, which may impact their market entry and sales potential [8].

重要内容提示： 转股情况： 截至 2025 年 6 月 30 日，累计已有人民币 719,000 元"健友转债"转为公司 普通股，累计回售人民币 7,000 元"健友转债"。"健友转债"累计转股股数 18,035 股，占转股前公司股份总额的 0.001%。 未转股可转债情况： | 证券代码：603707 | 证券简称：健友股份 | 公告编号：2025-060 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 关于"健友转债"转股结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 截至 2025 年 6 月 30 日，尚未转股的"健友转债"金额为人民币 502,464,000 元，占"健友转债"发行总量的比例为 99.86%。 一、可转债的发行上市概况 经中国证券监督管理委员会《关于核准南京健友生化制药股份有限公司公开 发行可转换公司债券的批复》（证监许可[2020]603 号）核准，南京健友生化制 药股份有限公司（以下简 ...

Core Viewpoint - Jingze Biopharmaceutical (Hefei) Co., Ltd. has submitted its prospectus for an IPO on the Hong Kong Stock Exchange, facing challenges due to significant losses and a reliance on a single approved drug while having multiple candidates in development [1][8]. Group 1: Company Overview - Jingze Biopharmaceutical was established in 2014, focusing on assisted reproduction and ophthalmic drugs, and is one of the leading companies in China for clinical-stage macromolecule drugs in these fields [2][3]. - The company has eight drug candidates, with only one product, JZB30, approved for commercialization in the assisted reproduction sector [3][4]. Group 2: Product Pipeline - JZB30, a recombinant human follicle-stimulating hormone lyophilized powder injection, was approved by the National Medical Products Administration in April 2025, targeting the global ovulation market [3]. - JZB33, a biosimilar to the imported drug Ganirelix, has completed bioequivalence studies and an NDA has been submitted [4]. - In the ophthalmic sector, JZB05, an anti-VEGF intravitreal injection, is in Phase III clinical trials, with an NDA submission expected in the second half of 2026 [4]. Group 3: Financial Performance - Jingze Biopharmaceutical reported losses of CNY 246 million and CNY 243 million for 2023 and 2024, respectively, with R&D expenses of CNY 122 million and CNY 133 million [5]. - As of the end of 2024, the company had cash and cash equivalents of CNY 68.59 million, with net current liabilities increasing to CNY 1.325 billion [5]. Group 4: Funding and Future Plans - The company has raised a total of CNY 927 million through various funding rounds from 2018 to 2023, with a post-investment valuation of CNY 3.09 billion in the C+ round [5]. - The IPO proceeds are intended to advance clinical trials and production development for multiple pipelines [5]. Group 5: Operational Challenges - Jingze Biopharmaceutical relies heavily on third-party contract research organizations (CROs) for preclinical and some clinical trials, which poses risks related to timely delivery and compliance [6]. - The company plans to establish a sales network in collaboration with well-known domestic pharmaceutical companies to distribute JZB30 and has partnered with Nanjing Jianyou for U.S. market registration of JZB33 [6]. Group 6: Market Strategy - The company aims to build a business team to assist partners in market development, although this requires significant time and funding [7]. - The success of the company is highly dependent on the successful development and commercialization of its drug candidates, which are primarily in preclinical or clinical stages [7].

Group 1 - The core viewpoint of the announcement is that the credit rating for Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd.'s convertible bonds remains unchanged at "AA" with a stable outlook [2][3]. - The previous rating for "Jianyou Convertible Bonds" was also "AA" with a stable outlook, indicating consistency in the company's creditworthiness [3]. - The tracking credit rating was conducted by United Credit Rating Co., Ltd., which assessed the company's business, management, and financial situation before issuing the report on June 27, 2025 [3]. Group 2 - The announcement confirms that the company's credit rating and the rating for the convertible bonds have not changed since the last assessment on June 26, 2024 [2][3]. - The report is available for further details on the Shanghai Stock Exchange website [3]. - The announcement was officially made by the board of directors of Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. on June 28, 2025 [5].

Core Viewpoint - Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. maintains a stable credit rating of AA for both the company and its convertible bonds, reflecting its strong market position in heparin production and sales, despite facing challenges in raw material pricing and market fluctuations [1][3][4]. Company Overview - The company specializes in the research, production, and sales of a full range of heparin products, including heparin sodium raw materials and low molecular weight heparin preparations, along with anti-tumor preparations and other sterile injectables [7][12]. - As of the end of 2024, the company reported total assets of 95.10 billion yuan and total equity of 64.88 billion yuan, with an operating income of 39.24 billion yuan and a profit of 9.92 billion yuan [7][12]. Financial Performance - In 2024, the company achieved a total profit of 9.92 billion yuan, recovering from a loss in the previous year, with a gross profit margin of 43.28%, although this was a decline from 48.45% in 2023 [5][14]. - The company’s total debt decreased by 20.68% to 20.79 billion yuan by the end of 2024, with a cash-to-short-term debt ratio of 1.67, indicating strong liquidity [5][14]. Market Position and Industry Analysis - The global heparin market is projected to grow at a compound annual growth rate (CAGR) of 5% to 7%, driven by an aging population and increasing prevalence of cardiovascular diseases [11][12]. - The company holds a competitive advantage in research and development, with 49 ongoing projects and a research investment of 532 million yuan, accounting for 13.57% of total revenue in 2024 [4][5]. Risks and Challenges - The company faces risks related to raw material supply, currency fluctuations, and trade tensions, particularly with a significant portion of its revenue (76.75% in 2024) coming from overseas sales [4][6]. - The price of standard heparin raw materials has been on a downward trend, impacting the company's revenue from this segment, which decreased by 21.05% to 7.87 billion yuan in 2024 [14][19]. Future Outlook - The company is expected to enhance its competitive edge as it expands its formulation business and continues to launch new pharmaceutical products [3][11]. - The stable cash reserves and reduced debt burden suggest that the company’s ability to service its convertible bonds will remain strong, with potential for credit rating upgrades if overseas market expansion and capital strength improve significantly [3][4].

Group 1 - The company, Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd., has announced the results of the credit rating for its convertible bonds, maintaining a rating of "AA" for both the bonds and the company itself, with a stable outlook [1][2] - The previous tracking rating for the "Jianyou Convertible Bonds" was conducted on June 26, 2024, with the same ratings of "AA" and a stable outlook [1] - The credit rating agency, United Credit Rating Co., Ltd., performed a comprehensive analysis of the company's business, management, and financial conditions before issuing the 2025 tracking rating report on June 27, 2025 [2]

重要内容提示： | 证券代码：603707 | 证券简称：健友股份 | 公告编号：2025-059 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 关于公司公开发行可转换公司债券 2025年跟踪评级结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 ●本次评级结果未发生调整。 ●前次"健友转债"评级：AA；主体评级：A A；评级展望：稳定； 本次"健友转债"评级：AA；主体评级：A A；评级展望：稳定。 根据《上市公司证券发行管理办法》等有关规定，南京健友生化制药股份有 限公司（以下简称"公司"）委托信用评级机构联合资信评估股份有限公司对公 司 2020 年 4 月发行的可转换公司债券（以下简称"健友转债"）进行了跟踪信 用评级。 "健友转债"前次跟踪评级时间为 2024 年 6 月 26 日，前次公司主体信用评 级结果为"AA"、前次评级展望为"稳定"，前次"健友转债"债券信用等级 为"AA"，评级机构为联合资信评估股份有限公 ...

南京健友生化制药股份有限公司 公开发行可转换公司债券 2025 年跟踪评级报告 1 www.lhratings.com 联合〔2025〕5678 号 联合资信评估股份有限公司通过对南京健友生化制药股份有限 公司主体及其相关债券的信用状况进行跟踪分析和评估，确定维持 南京健友生化制药股份有限公司主体长期信用等级为 AA，维持"健 友转债"信用等级为 AA，评级展望为稳定。 特此公告 联合资信评估股份有限公司 评级总监： 二〇二五年六月二十六日 声 明 一、本报告是联合资信基于评级方法和评级程序得出的截至发表之日的 独立意见陈述，未受任何机构或个人影响。评级结论及相关分析为联合资信 基于相关信息和资料对评级对象所发表的前瞻性观点，而非对评级对象的事 实陈述或鉴证意见。联合资信有充分理由保证所出具的评级报告遵循了真 实、客观、公正的原则。鉴于信用评级工作特性及受客观条件影响，本报告 在资料信息获取、评级方法与模型、未来事项预测评估等方面存在局限性。 二、本报告系联合资信接受南京健友生化制药股份有限公司（以下简称 "该公司"）委托所出具，除因本次评级事项联合资信与该公司构成评级委 托关系外，联合资信、评级人员与该公司 ...

南京健友生化制药股份有限公司 关于"健友转债"可选择回售结果的公告 债券代码：113579 债券简称：健友转债 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 责任。 重要内容提示： | 股票简称：健友股份 | 公告编号：2025-058 | | --- | --- | | 股票代码：603707 | | （一）回售结果 "健友转债"的回售申报期为 2025 年 6 月 17 日至 2025 年 6 月 23 日，回售 价格为 100.30 元/张（含当期应计利息、含税）。根据中国证券登记结算有限责 任公司上海分公司提供的数据，本次"健友转债"回售申报期内，回售的有效申 报数量为 0 张，回售金额为 0 元（含当期应计利息、含税）。公司无需办理向投 资者支付回售资金等后续业务事项，本次回售已完成。 （二）回售的影响 本次"健友转债"回售金额为 0 元，不会对公司现金流、资产状况、股本情 况等方面产生重大影响。 一、本次可转债回售的公告情况 南京健友生化制药股份有限公司（以下简称"公司"）于 2025 年 6 月 10 日披露了 ...